Circadian Influence on Prolonged Exposure Therapy for PTSD

Last updated: June 30, 2025
Sponsor: Massachusetts General Hospital
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Post-traumatic Stress Disorders

Treatment

Prolonged Exposure Therapy for Posttraumatic Stress Disorder

Clinical Study ID

NCT05453162
2021p003356
R21MH128619
  • Ages 18-70
  • All Genders

Study Summary

Proposed research will examine time-of-day effects on trauma-related fear extinction using Prolonged Exposure Therapy (PE) telemedicine for Posttraumatic Stress Disorder (PTSD) in the National Center for PTSD (NCPTSD). The primary mechanistic outcome measure will be change in psychophysiological reactivity to script-driven imagery (SDI-PR) measured, in person, at pre-treatment, after 5 PE sessions (mid-treatment), and after all 10 PE sessions (post-treatment). A secondary mechanistic outcome will be session-to-session reduction in peak subjective units of distress (SUDS) ratings to imaginal exposures. The primary clinical outcome will be change in Clinican Administered PTSD Scale (CAPS-5) severity score; a secondary clinical outcome will be session-to-session reduction in self-reported PTSD symptoms using the PTSD checklist (PCL-5). Participants meeting inclusion criteria (described below) will be randomized to either PE sessions that begin from 07:00 to a time no later than 2 hours past a participant's customary rise time, or to the last treatment session of the day beginning at 16:00 or later (26 per arm). Participants will complete daily at-home imaginal-exposure homework within the same time frame as their PE sessions are scheduled, i.e., within 2 hours of awakening for morning (AM) group and between 16:00 and 2 hours before bedtime for late afternoon (PM) group.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. a diagnosis of PTSD as defined by DSM-5, with a minimum CAPS severity score of 26, aminimum PCL-5 score of 31, or a score of 2 or above on CAPS-5 Item B2 (concerningdistressing dreams)

  2. interest in starting a course of PE

  3. availability for appointments at that will either begin from 07:00 to a time nolonger than 2 hours past their customary rise time, or to the last treatment sessionof the day beginning at 16:00 or later

  4. Age range of 18-70

  5. A Morningness-Eveningness Questionnaire (MEQ) score above 25.

  6. Non-exclusionary psychotropic medications must have been stable for 3 weeks prior toScreening/Assessment with intention to remain stable throughout participation.

Exclusion

Exclusion Criteria:

  1. current or past history of bipolar I disorder, schizophrenic or other psychoticdisorders,

  2. current organic brain disorder including moderate to severe traumatic brain injury

  3. factitious disorder or malingering

  4. pregnant or planning to become pregnant in the next four months at time of screening [if a participant does become pregnant during study procedures, the situation willbe reviewed on a case-by-case basis and the participant's wishes will be consideredin deciding whether the participant will continue with the study or withdraw.]

  5. current moderate or severe substance use disorder with symptoms present within thepast three months

  6. diagnosed moderate to severe sleep apnea, narcolepsy, periodic limb movement, orrestless legs syndrome that result in daytime sleepiness indicated by EpworthSleepiness Scale (ESS) above 10

  7. active risk of harm to self or others

  8. evidence of clinically significant hepatic or renal disease or any other acute orunstable medical condition that might interfere with safe conduct of the study

  9. current participation in trauma-focused cognitive-behavioral therapy (e.g.,Cognitive Processing Therapy, Written Exposure Therapy, Eye Movement Desensitizationand Reprocessing Therapy)

  10. prior treatment with an adequate dose of PE (i.e., 8 or more sessions) to thetraumatic event that would be the index trauma for treatment in the study

  11. having no memory of their traumatic event

  12. daily use of benzodiazepines

  13. methadone or suboxone maintenance therapy for past opioid addiction

  14. diagnosis of Cushing's disease, Addison's disease or use of medications that targetcortisol directly such as those used to treat Cushing's disease [ketoconazole,mitotane (Lysodren), metyrapone (Metopirone), and Mifepristone (Korlym, Mifeprex)],those used to treat Addison's disease [Hydrocortisone (Cortef), prednisone ormethylprednisolone], as well as cortisone or dexamethasone.

  15. persons who would habitually awaken so early that more than 2 h would elapse beforea morning PE session could occur; or those who engage in habitual shiftwork ortransmeridian travel

Study Design

Total Participants: 52
Treatment Group(s): 1
Primary Treatment: Prolonged Exposure Therapy for Posttraumatic Stress Disorder
Phase:
Study Start date:
July 01, 2022
Estimated Completion Date:
August 15, 2025

Study Description

Proposed research will examine time-of-day effects on trauma-related fear extinction using PE therapy for PTSD in the National Center for PTSD (NCPTSD). The primary mechanistic outcome measure will be change in SDI-PR; a secondary mechanistic outcome will be session-to-session reduction in peak SUDS ratings to imaginal exposures. The primary clinical outcome will be change in CAPS-5 severity score; a secondary clinical outcome will be session-to-session reduction in self-reported PTSD symptoms (PCL-5). Participants meeting inclusion criteria (described below) will be randomized to either PE sessions that begin from 07:00 to a time no later than 2 hours past a participant's customary rise time, or to the last treatment session of the day beginning at 16:00 or later. Participants will complete daily at-home imaginal-exposure homework within the same time frame as their PE sessions are scheduled (i.e., within 2 hours of awakening for morning group and between 16:00 and 2 hours before bedtime for late afternoon group). The assessment schedule will be identical for all participants. Participants who meet study inclusion criteria at screening will first begin a 7-day, pre-study sleep-monitoring period with wrist actigraphy, sleep diaries and completion of a diurnal profile of salivary cortisol levels. Trauma-related fear will be assessed using the standard SDI procedures detailed below at pre-treatment, after 5 PE sessions (mid-treatment), and after all 10 PE sessions (post-treatment). The CAPS-5 will be administered at these same times. PCL-5 measurements will be obtained at each treatment session and SUDs will be obtained during all treatment sessions that include imaginal exposure (sessions 3-8). All SDI sessions will be carried out at a standardized time of day in the late-afternoon (15:00-17:00). PE treatment will be administered at a targeted rate of once per week. At each PE and assessment session, pre-session saliva samples will be obtained for cortisol measurement and normalized using the diurnal profile of cortisol obtained during the sleep-assessment week. Participants will wear the wrist actigraph and complete sleep diaries throughout PE. The diurnal cortisol profile will be repeated at the post-treatment assessment.

Connect with a study center

  • VA Boston Healthcare System

    Boston, Massachusetts 02130-4817
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.